Furthermore, METTL3 inhibitor combined with anti-PD1 therapy promoted immunotherapy of CESC in vivo, which could be a potential therapeutic target in anticancer immunotherapy. The gene discussed is METTL3; the disease is cervical squamous cell carcinoma.